Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort
- PMID: 34125067
- PMCID: PMC8107834
- DOI: 10.1016/j.cmi.2021.03.012
Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort
Abstract
Objectives: Persistent COVID-19 symptoms have been reported up to 3 months after hospital discharge. Little is known on the frequency and the nature of persistent symptoms beyond 3 months. Here we have assessed, in the longitudinal prospective French COVID-19 cohort, symptoms that persisted 6 months after admission for COVID-19.
Methods: Hospitalized patients with virologically confirmed COVID-19 were enrolled. Follow-up was planned with a physician's visit at month (M)3 and M6 after admission. Associations between persistence of symptoms at M6 and clinical characteristics at admission were assessed through bivariate and multivariate logistic regression.
Results: M6 data were available for 1137 participants. Median age was 61 years (IQR 51-71) and 288 (29%, 95% CI 26-32%) were admitted to intensive care unit (ICU) during the acute phase. Six hundred and fifty-five (68%, 95% CI 65-71%) and 639 (60%, 95% CI 57-63%) participants had at least one symptom at M3 and M6 visit, respectively, mostly fatigue, dyspnoea, joint pain and myalgia. At M6, 255 (24%, 95% CI 21-27%) of participants had three or more persistent symptoms. The presence of three or more symptoms at M6 was independently associated with female gender (adjusted odds ratio (aOR) 2.40, 95% CI 1.75-3.30), having three or more symptoms at admission (aOR 2.04, 95% CI 1.45-2.89) and ICU admission/transfer during acute phase (aOR 1.55, 95% CI 1.09-2.18), but not significantly with age or having two or more comorbidities. One hundred and twenty-five (29%, 95% CI 25-34%) of those who initially had a professional occupation were not back to work at M6.
Discussion: A fourth of individuals admitted to hospital for COVID-19 still had three or more persistent symptoms at M6. Longitudinal follow-up of individuals with severe COVID-19 is warranted to better understand the pathophysiology underlying this long-term persistence.
Keywords: COVID-19 symptoms; Cohort; Emerging infectious diseases; Long-lasting COVID-19; SARS-CoV-2.
Copyright © 2021 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Figures
References
-
- Yazdanpanah Y., French COVID cohort investigators and study group Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID-19 patients. J Med Virol. 2021 Apr;93(4):2149–2159. doi: 10.1002/jmv.26601. Epub 2020 Nov 10. PMID: 33058220; PMCID: PMC7675272. - DOI - PMC - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
